Sarepta Therapeutics is navigating a transition from a profitable rare-disease company to a capital-intensive, multi-platform ...
Thank you for joining this conference call to present the results as of December 31, 2025 for Iren. The results will be presented by the Executive President, Luca dal Fabbro; and by the CFO, Giovanni ...
Revenue Growth Driving Group to Record EBITDA • Revenue of $186.5 million with organic revenue growth of 6.2% • Record Adjusted EBITDA of $45.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results